Nomograms for predicting cancer-specific survival in patients with primary central nervous system lymphoma: a population-based analysis

Chuanwei Yang[1]^, Xiaohui Ren[1], Yong Cui[1], Haihui Jiang[1], Kefu Yu[2], Mingxiao Li[1], Xuzhe Zhao[1], Qinghui Zhu[1], Song Lin[1]

[1]Department of Neurosurgery, Beijing Tiantan Hospital of Capital Medical University, Beijing Neurosurgical Institute, China National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brain Tumor, Beijing, China; [2]Department of Pharmacy, Beijing Tiantan Hospital of Capital Medical University, Beijing, China

Contributions: (I) Conception and design: S Lin, C Yang; (II) Administrative support: H Jiang, K Yu; (III) Provision of study materials or patients: X Ren, Y Cui; (IV) Collection and assembly of data: M Li, X Zhao, Q Zhu; (V) Data analysis and interpretation: C Yang, X Ren, S Lin; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Song Lin. Department of Neurosurgery, Beijing Tiantan Hospital of Capital Medical University, Beijing Neurosurgical Institute, China National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brain Tumor, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, China. Email: linsong2005@126.com.

Background: This study identified the risk factors for survival in patients with primary central nervous system lymphoma (PCNSL). Nomograms were developed and validated to predict individualized overall survival (OS) and cancer-specific survival (CSS) in this particular cohort.

Methods: Patients diagnosed with PCNSL between 1975 and 2016 were selected from the Surveillance, Epidemiology, and End Results (SEER) database for this study. The Cox regression model, the Fine and Grey's model, and the backward method were applied to determine the risk factors for OS and CSS. Nomograms were established accordingly. Internal and external validation was performed in an Asian population to examine the accuracy of the nomograms.

Results: A total of 5,900 patients with PCNSL were identified from the SEER database. A further 163 patients with PCNSL from the Beijing Tiantan Hospital between 2004 and 2018 were included. Age at diagnosis, tumor site, pathological subtype, surgery, chemotherapy, coexisting malignancies, and HIV infection were independent risk factors of CSS. In addition to the risk factors of CSS, gender, marital status, and radiation were also independent factors of OS. Nomograms were developed to estimate the 1-, 3-, and 5-year OS and CSS. The discrimination and calibration of the nomograms performed well. The C-indexes of the nomograms for OS and CSS prediction were 0.728 [95% confidence interval (CI): 0.703–0.753] and 0.726 (95% CI: 0.696–0.756), respectively. In addition, compared with previously published OS nomograms, the newly established nomograms displayed superior prediction for OS.

Conclusions: Nomograms predicting the 1-, 3- and 5-year OS and CSS of patients with PCNSL were established in this study. The validated nomograms showed relatively good performance and may be used clinically to evaluate patients' individualized risk and prognosis with PCNSL. Free software for individualized survival prediction is provided at http://www.pcnsl-survivalprediction.cn.

Keywords: Primary central nervous system lymphoma (PCNSL); overall survival (OS); cancer-specific survival (CSS); nomogram; individualized survival prediction

^ ORCID: 0000-0003-0448-8843.

Page 2 of 14

Yang et al. Nomograms to predict the prognosis of PCNSL

Introduction

Primary central nervous system lymphoma (PCNSL) is a rare and lethal lymphoma confined to the central nervous system (CNS). It accounts for 4–5% of all primary CNS tumors and 4–6% of all non-Hodgkin's lymphomas (1-3). The annual incidence of PCNSL is 0.5 per 100,000, and there are approximately 1,500 newly diagnosed cases in the United States each year (3). Unfortunately, the incidence of PCNSL continues to increase gradually (4). PCNSL exhibits an aggressive course and poor prognosis, with a 5-year survival of only 15–30% (5). However, there is still no ideal tumor staging or prognostic model that can satisfactorily predict the prognosis of PCNSL, with most clinicians relying on their clinical experience alone.

PCNSL mainly occurs in people over the age of 60 years (1). However, many patients in this age group also present with a high rate of comorbidities (6,7). With the prolonged survival of patients with PCNSL, the morbidity and mortality related to these other comorbidities also increase (8,9). Cancer-specific deaths reflect the progress of cancer itself and the impact on prognosis, while non-cancer-specific deaths are competing factors that affect the survival of cancer patients. Therefore, it is essential to consider such competing risks when evaluating the prognosis of patients with PCNSL. The ability to evaluate censored information enables competitive risk analysis to better predict prognosis (10).

In this study, big data from the Surveillance, Epidemiology, and End Results (SEER) database, in conjunction with data from our hospital, were analyzed to determine the prognostic risk factors and develop nomograms to predict overall survival (OS) and cancer-specific survival (CSS) in patients with PCNSL. We present the following article in accordance with the TRIPOD reporting checklist (available at https://dx.doi.org/10.21037/atm-21-753).

Methods

Patient data collection

PCNSL patients were identified from the SEER database according to the International Classification of Diseases for Oncology Third Edition (ICD-O-3) histology codes (9590–9599, 9670–9699, 9700–9719, 9720–9729) and anatomic location (C71.0–C71.9) (Figure S1). The analysis of PCNSLs was restricted to primary cancers, and secondary CNS lymphomas were excluded. Patients diagnosed without histological confirmation or diagnosed by autopsy

were excluded. Patients with unknown survival information were also excluded. Human immunodeficiency virus (HIV) infection status and coexistence of other malignancies were included, which allowed a real-world study to be conducted using a large cohort. The same inclusion and exclusion criteria were applied to patients from the Beijing Tiantan Hospital. This study was conducted following the Declaration of Helsinki (as revised in 2013) and was approved by the Ethics Committee of the Beijing Tiantan Hospital (No.: YW2019-016-11). Individual patient consent was waived.

Definition of variables

The patient demographics obtained included age at diagnosis (0–59, 60–74, ≥75 years), gender (male or female), race (white, black, other/unknown), marital status (married, divorced, single, widowed, other/unknown), coexisting malignancies (no, yes), and HIV infection (negative, positive). Tumor variables (tumor site and histological subtype), treatment variables (surgery, radiotherapy, and chemotherapy), and survival information were also collated. The tumor site was divided into a supratentorial, infratentorial, overlapping lesion of the brain, and not-otherwise-specified (NOS) regions of the brain. Tumor histological subtypes were grouped as diffuse large B cell lymphoma (DLBCL), non-diffuse large B-cell lymphoma (non-DLBCL), or not-otherwise-specified lymphoma (lymphoma, NOS). According to the surgery codes for the brain in the SEER database, the surgical treatments were categorized as biopsy, subtotal resection (STR), gross total resection (GTR), partial lobectomy, lobectomy, and surgery of unknown type. Patients who died of HIV infection or Kaposi sarcoma were considered positive for HIV infection. OS was defined as the time from diagnosis to last follow-up or death from any cause. CSS was defined as the time from the date of diagnosis to death due to PCNSL.

Statistical analysis

The cumulative incidence function (CIF) was used to describe the probability of cancer-specific death and competing death (11). The Gray's test was used to compare differences in CIF between groups (12). OS was analyzed using the Kaplan-Meier method and compared by log-rank tests. Univariate analysis was conducted to obtain factors significantly related to OS, which were then analyzed by multivariate analyses. The Fine and Gray model was

utilized to determine factors significantly related to CSS (13,14). The backward method was then used to select the independent prognostic factors used to establish the nomograms (15). Harrell's concordance indexes (C-indexes), receiver operating characteristic curve (ROC curves), and calibration curves were used to measure the performance of the nomograms. All statistical analyses were performed using R version 3.6.3 software. Two-tailed distribution with a P value <0.05 was considered statistically significant.

Results

Patient characteristics

From 6,042 patients with intracranial PCNSL who were identified from the SEER database between 1975 and 2016, a total of 5,900 patients were enrolled in this study. The patients were allocated into the training set (n=4,131) and the validation set (n=1,769) at a ratio of 7:3. A consecutive cohort of 163 patients with PCNSL admitted to the Beijing Tiantan Hospital between 2004 and 2018 was included as an external validation set. Baseline patient characteristics are shown in *Table 1*. All clinicopathological characteristics were comparable between patients in the training set and patients in the validation set (Table S1). Overall, 57.4% of the patients were male, and Caucasians accounted for 79.7% of the total study population. Most of the patients (54.1%) were aged 60 years and older, 45.9% were younger than 59 years. More than half of the patients were married, 25.4% were single, 10.1% were widowed, 7.7% were divorced, and 4.5% were in other relationships, for example, separated or domestic partnership. More than half of the tumors were supratentorial, and DLBCL (n=4,247, 72.0%) was the most common subtype. A total of 4,394 (74.5%) patients received biopsies, 17.0% received surgical resection, and 8.5% received surgery of unknown type, most of which could be biopsied. More than half (54.1%) of the patients received chemotherapy, while less than half (45.1%) received radiotherapy. The vast majority of patients had only one primary malignant tumor (96.4%) and were HIV negative (84.6%).

In total, 4,589 deaths occurred during the follow-up period of 27.7 months (range, 0–469 months), of which 4,030 were cancer-specific deaths, and 559 were competing deaths. The corresponding CIF curves are shown in Figure S2. The 1-, 3-, and 5-year cancer-specific mortalities were 50.8%, 63.2%, and 68.6%, respectively, while the competing mortalities were 4.6%, 6.3%, and 7.5%,

respectively. The cumulative probability of death from PCNSL increased with increasing age at diagnosis. The cumulative incidences of competing death also increased with increasing age. The following risk factors significantly increased the probability of PCNSL-specific death: males, black people, single or widowed, overlapping tumor site, DLBCL, biopsy, no radiation, no chemotherapy, HIV positive, and only one primary malignant tumor. Patients with divorced or widowed families who did not undergo chemotherapy and presented with coexisting malignancies were more likely to die of competing causes (*Table 1*).

Kaplan-Meier analysis and correlation analysis

Kaplan-Meier analysis showed significant differences in OS rates when stratified by these characteristics above (*Figure 1*). Patients with the following characteristics showed significantly better OS: younger age, female, other race, married, supratentorial site, non-DLBCL, GTR, no radiation, chemotherapy, coexisting malignancies, and HIV negative. The risk coefficients of patients were scored by the Cox regression analysis, and patients were divided into a high-risk group and a low-risk group according to the median value. The survival difference between the high- and low-risk groups was statistically significant (*Figure 1*). The correlation between these different risk factors is shown in Figure S3. With the increase in time, patients diagnosed with PCNSL were older at the time of diagnosis. The number of patients receiving surgery and radiotherapy decreased, and the number of patients receiving chemotherapy increased. More unmarried younger men were HIV-positive and had shorter survival times.

Univariate and multivariate analysis of factors for OS and CSS

As shown in *Table 2*, univariate analysis for OS revealed that age, gender, race, marital status, tumor site, subtype, surgery, radiation, chemotherapy, coexisting malignancies, and HIV infection status were all significantly associated with survival. The univariate competing risk analysis also showed that all the characteristics were significantly associated with CSS. These risk factors were further incorporated into the multivariate analysis, which demonstrated that the independent prognostic factors of OS were age, gender, marital status, tumor site, subtype, surgery, radiation, chemotherapy, coexisting malignancies, and HIV infection status. In contrast to OS, the

Page 4 of 14

Yang et al. Nomograms to predict the prognosis of PCNSL

Table 1 Overall survival rates and cumulative incidences of cancer-specific death and competing death among patients with PCNSL in the overall dataset

Characteristic	Subcategory	Patients		Overall survival rate (%)				Cancer-specific death (%)				Competing death (%)			
		No.	%	1-year	3-year	5-year	P	1-year	3-year	5-year	P	1-year	3-year	5-year	P
Total No.		5,900	100.0	44.6	30.5	23.9		50.8	63.2	68.6		4.6	6.3	7.5	
Age, years	0–59	2,707	45.9	47.5	36.1	30.2	<0.001	49.4	59.8	64.7	0.031	3.1	4.1	5.1	0.022
	60–74	2,138	36.2	48.6	31.2	22.5		47.0	62.4	69.6		4.4	6.4	7.9	
	75+	1,055	17.9	29.5	14.1	9.2		61.7	74.0	77.5		8.8	11.9	13.3	
Gender	Female	2,511	42.6	50.4	34.7	26.3	<0.001	45.5	59.3	66.1	<0.001	4.1	6.0	7.6	0.612
	Male	3,389	57.4	40.4	27.4	22.0		54.6	66.1	70.5		5.0	6.5	7.5	
Race	White	4,701	79.7	44.9	30.1	23.2	0.001	50.4	63.4	69.1	0.014	4.7	6.5	7.7	0.075
	Black	544	9.2	31.1	24.4	20.5		65.4	71.5	73.9		3.5	4.1	5.6	
	Other/ unknown	655	11.1	54.5	38.8	31.8		40.6	54.4	60.4		4.9	6.8	7.8	
Marital status	Married	3,083	52.3	51.6	35.8	28.0	<0.001	43.9	57.8	64.5	<0.001	4.5	6.4	7.5	<0.001
	Divorced	456	7.7	45.8	30.3	22.8		48.8	63.1	69.0		5.4	6.6	8.2	
	Single	1,500	25.4	34.4	25.0	21.1		62.1	70.5	73.5		3.5	4.5	5.4	
	Widowed	597	10.1	34.7	16.8	11.1		57.5	72.3	76.4		7.8	10.9	12.5	
	Other/ unknown	264	4.5	42.5	31.3	23.8		54.0	63.8	69.3		3.5	4.9	6.9	
Tumor site	Supratentorial	3,070	52.0	48.0	32.2	25.6	<0.001	47.7	61.5	66.8	<0.001	4.3	6.3	7.6	0.396
	Infratentorial	442	7.5	44.3	31.3	25.5		51.6	62.7	67.6		4.1	6.0	6.9	
	Overlapping	687	11.6	42.0	27.9	20.2		54.0	66.8	73.0		4.0	5.3	6.8	
	Brain, NOS	1,701	28.8	39.6	28.2	21.8		54.8	65.0	70.3		5.6	6.8	7.9	
Subtype	DLBCL	4,247	72.0	45.5	30.9	23.7	<0.001	50.0	62.7	68.6	<0.001	4.5	6.4	7.7	0.931
	Non-DLBCL	348	5.9	63.2	49.6	45.4		33.9	45.6	49.4		2.9	4.8	5.2	
	Lymphoma, NOS	1,305	22.1	36.9	24.0	18.6		57.7	69.7	73.9		5.4	6.3	7.5	
Surgery	Biopsy	4,394	74.5	41.2	27.5	21.7	<0.001	54.0	65.9	70.6	<0.001	4.8	6.6	7.7	0.762
	STR	220	3.7	57.6	49.1	40.7		39.0	45.6	52.3		3.4	5.3	7.0	
	GTR	198	3.4	75.3	57.1	50.3		20.9	38.3	42.3		3.8	4.6	7.4	
	Partial lobectomy	277	4.7	51.0	37.5	29.3		45.7	58.1	64.8		3.3	4.4	5.9	
	Lobectomy	311	5.3	60.1	43.9	36.1		36.0	49.9	57.0		3.9	6.2	6.9	
	Unknown-type	500	8.5	44.4	27.5	19.4		50.8	66.3	73.0		4.8	6.2	7.6	
Radiation	No	3,242	54.9	46.3	35.6	30.2	<0.001	48.6	57.8	61.9	<0.001	5.1	6.6	7.9	0.414
	Yes	2,658	45.1	42.9	25.2	17.8		53.1	68.9	75.2		4.0	5.9	7.0	
Chemotherapy	No	2,706	45.9	22.8	12.9	10.2	<0.001	70.1	78.3	80.1	<0.001	7.1	8.8	9.7	0.005
	Yes	3,194	54.1	63.3	45.8	35.8		34.2	50.1	58.7		2.5	4.1	5.5	
Coexistence with other malignancy	No	5,689	96.4	43.6	29.3	22.8	<0.001	51.9	64.6	70.0	<0.001	4.5	6.1	7.2	<0.001
	Yes	211	3.6	73.2	59.2	50.5		20.1	28.6	33.7		6.7	12.2	15.8	
HIV	Negative	4,993	84.6	51.1	35.5	28.0	<0.001	43.5	57.4	63.5	<0.001	5.1	7.1	8.5	0.235
	Positive	907	15.4	8.4	3.6	2.2		89.7	94.4	95.7		1.9	2.0	2.1	

PCNSL, primary central nervous system lymphoma; NOS, not otherwise specified; DLBCL, diffuse large B-cell lymphoma; STR, subtotal resection; GTR, gross total resection.

Figure 1 Kaplan-Meier analysis for overall survival stratified by age (A), gender (B), race (C), marital status (D), tumor site (E), tumor subtype (F), surgery (G), radiotherapy (H), chemotherapy (I), coexisting malignancies (J), HIV status (K), and risk level (L). The risk coefficients of patients were scored by Cox regression analysis, and the patients were divided into a high-risk group and a low-risk group using the median value. NOS, not otherwise specified; DLBCL, diffuse large B-cell lymphoma; STR, subtotal resection; GTR, gross total resection.

independent prognostic factors of CSS were age, tumor site, subtype, surgery, chemotherapy, coexisting malignancies, and HIV infection status (*Table 2*).

Construction and internal validation of nomograms for OS and CSS

The backward method was used to select the independent prognostic factors of the final models to construct the nomograms. The forest plots showing the prognostic factors' hazard ratios (HRs) are shown in Figure S4. The nomogram for predicting OS was established with a C-index

of 0.728 [95% confidence interval (CI): 0.703–0.753], and the nomogram for predicting CSS was established with a C-index of 0.726 (95% CI: 0.696–0.756) in the training cohort (*Figure 2*). The red points in the nomograms represent the scores and the 1-, 3-, and 5-year survival probability of the same patients in the OS and CSS nomogram. To facilitate individualized survival prediction, formulae for survival probability calculations were established (Table S2). Free software is available online (http://www.pcnsl-survivalprediction.cn), the friendly interface of which is shown in Figure S5.

During the validation of the nomograms, the risk

Table 2 Univariate and multivariate analyses of survival in patients with PCNSL in the training set

Factor	Subcategory	Overall survival						Cancer-specific survival					
		Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis		
		HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Age, years	0–59		Reference			Reference			Reference			Reference	
	60–74	1.122	1.038–1.214	0.004	1.693	1.539–1.862	<0.001	0.992	0.917–1.070	0.840	1.435	1.296–1.589	<0.001
	75+	1.813	1.651–1.992	<0.001	2.558	2.277–2.874	<0.001	1.347	1.219–1.490	<0.001	1.856	1.630–2.113	<0.001
Gender	Female		Reference			Reference			Reference			Reference	
	Male	1.224	1.141–1.313	<0.001	1.122	1.039–1.213	0.004	1.190	1.110–1.280	<0.001	1.004	0.926–1.089	0.930
Race	White		Reference			Reference			Reference			Reference	
	Black	1.260	1.119–1.419	<0.001	1.076	0.949–1.221	0.255	1.319	1.151–1.512	<0.001	–	–	–
	Other/unknown	0.764	0.680–0.860	<0.001	0.891	0.792–1.004	0.057	0.756	0.671–0.852	<0.001	–	–	–
Marital status	Married		Reference			Reference			Reference			Reference	
	Divorced	1.282	1.124–1.463	<0.001	1.213	1.061–1.388	0.005	1.250	1.090–1.420	0.001	1.137	0.981–1.317	0.088
	Single	1.396	1.285–1.517	<0.001	0.966	0.872–1.071	0.510	1.450	1.329–1.580	<0.001	0.991	0.887–1.106	0.870
	Widowed	1.610	1.438–1.802	<0.001	1.135	1.004–1.283	0.043	1.340	1.194–1.510	<0.001	1.021	0.889–1.172	0.770
	Other/unknown	1.223	1.024–1.460	0.027	0.991	0.828–1.186	0.924	1.150	0.938–1.400	0.180	0.947	0.777–1.154	0.590
Tumor site	Supratentorial		Reference			Reference			Reference			Reference	
	Infratentorial	1.036	0.901–1.192	0.616	1.119	0.828–1.215	0.186	1.050	0.906–1.210	0.530	1.058	0.902–1.242	0.490
	Overlapping	1.190	1.069–1.325	0.001	1.144	1.026–1.274	0.015	1.190	1.074–1.330	<0.001	1.161	1.043–1.292	0.006
	Brain, NOS	1.199	1.107–1.299	<0.001	1.173	1.081–1.273	<0.001	1.150	1.054–1.250	0.001	1.108	1.014–1.211	0.024
Subtype	DLBCL		Reference			Reference			Reference			Reference	
	Non-DLBCL	0.541	0.457–0.640	<0.001	0.525	0.442–0.622	<0.001	0.576	0.480–0.690	<0.001	0.594	0.492–0.717	<0.001
	Lymphoma, NOS	1.184	1.092–1.284	<0.001	0.918	0.844–0.999	0.048	1.142	1.50–1.240	0.002	0.911	0.832–0.998	0.046
Surgery	Biopsy		Reference			Reference			Reference			Reference	
	STR	0.603	0.473–0.769	<0.001	0.781	0.611–0.998	0.048	0.623	0.483–0.803	<0.001	0.820	0.633–1.064	0.140
	GTR	0.432	0.332–0.564	<0.001	0.513	0.393–0.670	<0.001	0.443	0.340–0.579	<0.001	0.530	0.400–0.703	<0.001
	Partial lobectomy	0.811	0.694–0.948	0.008	0.849	0.725–0.994	0.042	0.925	0.792–1.081	0.330	1.032	0.872–1.222	0.710
	Lobectomy	0.632	0.540–0.740	<0.001	0.719	0.613–0.843	<0.001	0.672	0.575–0.785	<0.001	0.773	0.647–0.924	0.005
	Unknown-type	0.893	0.794–1.004	0.059	0.859	0.760–0.971	0.015	0.926	0.825–1.039	0.190	0.921	0.815–1.041	0.190

Table 2 (continued)

Table 2 (*continued*)

Factor	Subcategory	Overall survival						Cancer-specific survival					
		Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis		
		HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Radiation	No		Reference			Reference			Reference			Reference	
	Yes	1.147	1.070–1.229	<0.001	0.835	0.774–0.901	<0.001	1.230	1.150–1.320	<0.001	0.976	0.900–1.059	0.560
Chemotherapy	No		Reference			Reference			Reference			Reference	
	Yes	0.368	0.343–0.395	<0.001	0.403	0.372–0.437	<0.001	0.463	0.430–0.498	<0.001	0.562	0.515–0.613	<0.001
Coexistence with other malignancy	No		Reference			Reference			Reference			Reference	
	Yes	0.592	0.490–0.714	<0.001	0.505	0.418–0.610	<0.001	0.414	0.331–0.519	<0.001	0.384	0.305–0.484	<0.001
HIV	Negative		Reference			Reference			Reference			Reference	
	Positive	3.254	2.975–3.560	<0.001	3.369	2.977–3.812	<0.001	3.290	3.010–3.590	<0.001	3.287	2.842–3.800	<0.001

PCNSL, primary central nervous system lymphoma; NOS, not otherwise specified; DLBCL, diffuse large B-cell lymphoma; STR, subtotal resection; GTR, gross total resection; NS, prognostic risk factors not selected with the backward method; HR, hazard ratio; 95% CI, confidence interval; HIV, human immunodeficiency virus.

scores of each patient in the validation cohort were firstly calculated according to the established Cox regression model by which the nomograms were constructed. Cox regression was then performed using the risk score as a factor. The ROC curves and calibration curves were derived based on the regression analysis. The calibration curves for OS prediction showed high consistency between the predicted survival and actual survival in both the training and internal validation sets. The calibration curves for CSS prediction also confirmed ideal consistency in the training set and internal validation set (*Figure 3*). The ROC curves of the nomograms for the 1-, 3-, and 5-year OS prediction and CSS prediction are shown in *Figure 4*. For the training set, the area under ROC curve (AUC) values for predicting the 1-, 3-, and 5-year OS rates were 0.799, 0.791, and 0.778, respectively, and the AUC values for predicting the 1-, 3-, and 5-year CSS rate were 0.801, 0.792, and 0.781, respectively. Similar results were obtained for the internal validation set and external validation set (*Figure 4*).

### External validation of nomograms

The external validation using the Asian patient cohort from our hospital showed that the established OS and CSS nomograms demonstrated good consistency between predicted survival and actual survival (*Figure 3*). The AUC values for predicting the 1-, 3-, and 5-year OS rate were 0.674, 0.742, and 0.805, respectively, and the values for predicting the 1-, 3-, and 5-year CSS rate were 0.689, 0.760, and 0.806, respectively (*Figure 4*). The deviation of the calibration curves and the irregular ROC curves in the external validation may be due to several reasons, including the relatively small sample size, the patients were all HIV-negative, most of the pathological subtypes were DLBCL, and there were no patients with partial lobectomy or lobectomy (Table S3).

Comparison of the OS nomogram

Comparing the discriminatory capacity between the present OS nomogram and the published Deng nomogram revealed that the former performed better than the latter (*Figure 5*). The AUC values of Deng's nomogram for predicting the 1-, 3-, and 5-year OS rates were 0.762, 0.758, and 0.744, respectively.

Subgroup analysis

To further explore the stability and validity of the

Figure 2 Nomograms for predicting overall survival (OS) (A) and cancer-specific survival (CSS) (B). The red points in the nomograms present the scores and the 1-, 3-, and 5-year survival probability of the same patients in the OS and CSS nomogram.

　　　　　　　　Ann Transl Med 2021;9(13):1055 | https://dx.doi.org/10.21037/atm-21-753

Figure 3 Calibration curves. (A,B,C) Calibration curves of the 1-, 3-, and 5-year overall survival (OS) nomogram for the training set (A), internal validation set (B), and external validation set (C). (D,E,F) Calibration curves of the 1-, 3-, and 5-year cancer-specific survival (CSS) nomogram for the training set (D), internal validation set (E), and external validation set (F).

nomograms, a subgroup analysis was conducted. Univariate and multivariate Cox analyses were performed in a cohort of patients with the only PCNSL and HIV negative. The prognostic factors of OS and CSS were the same as those in the training set. However, the C-index of the OS and CSS prognostic model constructed by the subgroup analysis were 0.697 and 0.685, respectively, which were inferior to those of the present nomograms (*Figure 6*). Other subgroup analyses of HIV infection (negative/positive) or coexistence of other malignancies (yes/no) yielded similar results (Figure S6).

Discussion

PCNSL is an aggressive brain tumor that has been evaluated in previous studies (1,16). However, such studies were either single-center studies with small sample sizes or failed to consider competing risks, resulting in misleading conclusions. Commonly used prognostic models for PCNSL, such as the International Prognostic Index (IPI), the International Extra-nodal Lymphoma Study Group prognostic score scale (IELSG score), and the New York Memorial Sloan Kettering Cancer Center score scale (MSKCC score), cannot satisfactorily determine the

prognosis of PCNSL patients (17). An ideal prediction model should include patient characteristics and tumor-related characteristics, and treatment-related characteristics (18). This current study considered all these factors in establishing well-calibrated prognostic nomograms to predict OS and CSS in patients with PCNSL. In addition, these prognostic models were based on the largest cohort of PCNSL patients, and the superior discriminative power of the nomograms was confirmed by the high C-index and AUC values, which were superior to that of other published OS nomogram of PCNSL (16). The present nomograms are the first prognostic nomograms for PCNSL that have been externally validated using a PCNSL database and in the Chinese population to the best of our knowledge.

The present nomograms developed in this report were superior to the models constructed in the subgroup analyses, as demonstrated by the better C-index and AUC values. However, when the present nomogram was applied to the Chinese cohort, its predictive performance was relatively reduced. This may be due to the heterogeneity of different data sets. In the OS nomogram, predictors of long-term survival for patients with PCNSL were younger age, female gender, married status, supratentorial, non-DLBCL, GTR,

Page 10 of 14

Yang et al. Nomograms to predict the prognosis of PCNSL

Figure 4 Receiver operating characteristic (ROC) curves. (A,B,C) ROC curves of the 1-, 3-, and 5-year overall survival (OS) nomogram for the training set (A), internal validation set (B), and external validation set (C). (D,E,F) ROC curves of the 1-, 3-, and 5-year cancer-specific survival (CSS) nomogram for the training set (D), internal validation set (E), and external validation set (F).

Figure 5 A comparison of the receiver operating characteristic (ROC) curves of the 1-year (A), 3-year (B), and 5-year (C) overall survival (OS) between the present OS nomogram and the published Deng's nomogram.

radiation, chemotherapy, coexisting malignancies, and HIV negative status. In the CSS nomogram, predictors of long-term survival for patients with PCNSL included younger age, supratentorial, non-DLBCL, GTR, chemotherapy, coexisting malignancies, and HIV negative status. Previous reports have suggested that age has a significant impact on

Figure 6 Forest plot showing subgroup analysis of overall survival (OS) (A) and cancer-specific survival (CSS) (B) in the patients with primary central nervous system lymphoma (PCNSL) only and human immunodeficiency virus (HIV) negative status.

survival (19). The present study suggested that age-related non-cancer-specific death was a competing risk, and the most common competing risks for PCNSL were cardiac diseases, cerebrovascular diseases, pneumonia and influenza, HIV, and accidents and adverse events. Therefore, it is important to evaluate treatment tolerance, such as surgery and radiotherapy, among older patients and to consider age when prognostic models are developed for patients with PCNSL.

Some studies have reported that the marital status of patients with PCNSL was significantly associated with survival and suggested that married status was a good prognosis (20). However, the present study demonstrated that marital status was only related to OS. When competing risks were included in the analysis, there was no significant correlation between marital status and prognosis. In patients with PCNSL presenting with comorbidities, the care and support from the spouse may improve their ability to fight multiple diseases. In the competing risks analysis, gender and radiotherapy were also not significantly related to prognosis. Radiotherapy only prolonged the progression-free survival (PFS) time, but not the OS time due to the delayed brain

damage (21). In the current study, PCNSL patients benefited most from chemotherapy, but radiotherapy had little effect. Tumors at the supratentorial site and non-DLBCL indicated a better prognosis, suggesting that DLBCL was the most malignant pathological subtype.

Surgical treatment has always been a controversial topic for PCNSL. Single-center clinical studies conducted before the 20th century with few cases suggested that PCNSL patients did not benefit from surgery (22). In the latest 2020 National Comprehensive Cancer Network (NCCN) Central Nervous System Cancer Guidelines, a biopsy is regarded as the "gold standard" for PCNSL, and surgical excision is recommended only in cases of rapid neurological deterioration resulting from an acute increase in intracranial pressure or when the cerebral hernia is imminent. However, the present study revealed that, compared with biopsies, patients with PCNSL could benefit from surgery, and the benefits of patients increased gradually as the scope of surgical resection expanded. Furthermore, patients receiving GTR benefited the most. However, the advantages from partial lobectomy and lobectomy were less

Page 12 of 14

Yang et al. Nomograms to predict the prognosis of PCNSL

obvious than that observed with STR, which may be due to the increased incidence of postoperative complications after major surgery, affecting a patient's prognosis. In a large randomized controlled trial in Germany in 2012, the PFS and OS of 526 PCNSL patients in the biopsy group were significantly shorter than in the STR and GTR groups, even after the patient's age and performance status (KPS score) were adjusted (23). Moreover, in a previous study, we found that PCNSL patients benefited the most from GTR and chemotherapy treatment regimen, even after the patient's age, gender, and pathological subtype were adjusted (24). Therefore, it is imperative to carry out prospective studies to determine whether patients with PCNSL can benefit from surgery.

In this study, HIV was considered a prognostic factor. The results showed that the risk of death in HIV-positive patients was 3.63 times greater than that of HIV-negative patients, indicating that HIV-positive PCNSL patients had unique biological characteristics. Continuous advancements in treatment methods have continued to extend the patient's survival period. Nowadays, adequate antiretroviral therapy has significantly reduced the prevalence of HIV-associated PCNSL, and as shown in Figure S3, the number of patients with HIV-positive PCNSL has decreased over time. Since the year of diagnosis does not have much significance in predicting the survival of patients, this was excluded from the nomogram as reported (16).

Additionally, it was interesting to note that the probability of long-term survival in patients with coexisting malignancies was higher than that in patients with PCNSL alone. This protective effect was still observed in the subgroup analyses (Figure S6). It is possible that treatment for other malignant tumors, such as immunotherapy and autologous stem cell transplantation, also exerted an inhibitory effect on PCNSL. Subgroup analysis of PCNSL patients with coexisting malignancies showed that age ≥75 years, radiation, and HIV positive status were all risk factors for prognostic (Figure S6). Further research into this complex situation is warranted in the future.

In recent years, competing risk nomograms have been developed for many tumors, such as lung cancer (11), prostate cancer (25), and gallbladder carcinoma (26). However, there has been no specific competing risk analysis for PCNSL. Therefore, the present study was the first to evaluate prognostic factors based on a competing risk analysis model for patients with PCNSL. The published Deng's nomogram only considered OS. When Deng's nomogram was applied to our data, the accuracy of the

predictions was significantly lower than the present nomogram. Nowadays, increasingly, patients with PCNSL participate in clinical trials of new therapies, such as immune checkpoint inhibitor PD-1 monoclonal antibody treatment. However, clinical trials have strict inclusion criteria and are only suitable for a small number of patients. Most patients still receive traditional radiotherapy and chemotherapy, and thus, the present nomogram has significant clinical value. The inclusion of competing risks in the analysis makes assessing the long-term survival of patients with PCNSL more accurate. Future research should investigate the association of OS and CSS with primary tumors and comorbidities. Since the SEER database does not provide detailed information on comorbidities, we cannot clarify which comorbidity can significantly affect the survival of patients with PCNSL.

There were several limitations in this study. First, some potential prognostic factors, such as KPS score, serum lactic dehydrogenase (LDH) levels, and lesion size, were not available in the SEER database and were therefore not included in the nomograms in this study. Second, as a retrospective study, treatment selection bias could not be avoided. For example, patients with a single supratentorial site, low surgical risk, and tumors misdiagnosed as gliomas were more likely to receive surgery.

Conclusions

In conclusion, this study reports the development of novel prognostic nomograms based on a large population cohort to estimate the OS and CSS for patients with PCNSL. The well-calibrated nomograms may promote patient management and patient counseling in clinical practice, better predict individualized survival, and promote the stratification of patients in subsequent clinical trials in the future. To facilitate the clinical use of this nomogram, free software for individualized survival prediction is provided (http://www.pcnsl-survivalprediction.cn).

Acknowledgments

Footnote

Reporting Checklist: The authors have completed the

TRIPOD reporting checklist. Available at https://dx.doi.org/10.21037/atm-21-753

Peer Review File: Available at https://dx.doi.org/10.21037/atm-21-753

References

1. Rae AI, Mehta A, Cloney M, et al. Craniotomy and Survival for Primary Central Nervous System Lymphoma. Neurosurgery 2019;84:935-44.
2. Villano J L, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011;105:1414-8.
3. Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol 2017;35:2410-8.
4. Mahale P, Herr MM, Engels EA, et al. Autoimmune conditions and primary central nervous system lymphoma risk among older adults. Br J Haematol 2020;188:516-21.
5. Kasenda B, Ferreri A J M, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol 2015;26:1305-13.
6. Han KR, Kim HL, Pantuck AJ, et al. Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology 2004;63:841-6.
7. Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005;55:231-40.
8. Zhang W, Hong HJ, Chen YL. Establishment of a gallbladder cancer-specific survival model to predict prognosis in non-metastatic gallbladder cancer patients after surgical resection. Dig Dis Sci 2018;63:2251-8.
9. Eguchi T, Bains S, Lee MC, et al. Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung cancer: a competing risks analysis. J Clin Oncol 2017;35:281-90.
10. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007;26:2389-430.
11. Zhang MJ, Zhang X, Scheike TH. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol 2008;1:391-400.
12. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
13. Kuk D, Varadhan R. Model selection in competing risks regression. Stat Med 2013;32:3077-88.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
15. Mogensen UB, Ishwaran H, Gerds TA. Evaluating random forests for survival analysis using prediction error curves. J Stat Softw 2012;50:1-23.
16. Deng X, Xu X, Lin D, et al. Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma. Front Oncol 2020;10:131.
17. Liu CJ, Lin SY, Yang CF, et al. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med 2020;9:2134-45.
18. Montero PH, Yu C, Palmer FL, et al. Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma. Cancer 2014;120:214-21.
19. He C, Zhang Y, Cai Z, et al. Nomogram to predict cancer-specific survival in patients with pancreatic acinar cell carcinoma: a competing risk analysis. J Cancer 2018;9:4117-27.

Page 14 of 14

Yang et al. Nomograms to predict the prognosis of PCNSL

20. Norden AD, Drappatz J, Wen PY, et al. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol 2011;101:487-93.
21. Schlegel U, Korfel A. Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas? Curr Opin Neurol 2018;31:733-9.
22. Hayakawa T, Takakura K, Abe H, et al. Primary central nervous system lymphoma in Japan--a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 1994;19:197-215.
23. Kreher S, Strehlow F, Martus P, et al. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. Ann Hematol 2015;94:409-414.
24. Yang CW, Ren XH, Jiang HH, et al. Different treatment regimens for primary central nervous system lymphoma:based on SEER database. Zhonghua Wai Ke Za Zhi 2021;59:52-8.
25. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31:1748-57.
26. He C, Cai Z, Zhang Y, et al. Prognostic Model to Predict Cancer-Specific Survival for Patients With Gallbladder Carcinoma After Surgery: A Population-Based Analysis. Front Oncol 2019;9:1329.

Table S1 The comparison between the training set and the validation set

Characteristic	Subcategory	No.	Subgroup		P
			Training set	Validation set	
Total No.		5,900	4,131	1,769	
Status	Alive	1,311	898	413	0.396
	Cancer-specific mortality	4,030	2,839	1,191	
	Competing mortality	559	394	165	
Age, years	0–59	2,707	1,903	804	0.840
	60–74	2,138	1,487	651	
	75+	1,055	741	314	
Gender	Female	2,511	1,768	743	0.570
	Male	3,389	2,363	1,026	
Race	White	4,701	3,294	1,407	0.608
	Black	544	372	172	
	Other/unknown	655	465	190	
Marital status	Married	3,083	2,130	953	0.448
	Divorced	456	319	137	
	Single	1,500	1,073	427	
	Widowed	597	427	170	
	Other/unknown	264	182	82	
Tumor site	Supratentorial	3,070	2,143	927	0.088
	Infratentorial	442	289	153	
	Overlapping	687	496	191	
	Brain, NOS	1,701	1,203	498	
Subtype	DLBCL	4,247	2,991	1,256	0.528
	Non-DLBCL	348	242	106	
	Lymphoma, NOS	1,305	898	407	
Surgery	Biopsy	4,394	3,079	1,315	0.092
	STR	220	138	82	
	GTR	198	136	62	
	Partial lobectomy	277	208	69	
	Lobectomy	311	222	89	
	Unknown-type	500	348	152	
Radiation	No	3,242	2,263	979	0.691
	Yes	2,658	1,868	790	
Chemotherapy	No	2,706	1,898	808	0.562
	Yes	3,194	2,333	961	
Coexistence with other malignancy	No	5,689	3,982	1,707	0.847
	Yes	211	149	62	
HIV	Negative	4,993	3,489	1,504	0.584
	Positive	907	642	265	

NOS, not otherwise specified; DLBCL, diffuse large B-cell lymphoma; STR, subtotal resection; GTR, gross total resection; HIV, human immunodeficiency virus.

Table S2 Formulae for the calculation of survival probability

Overall survival

  Model =0

    +0 (if age, 0–59)

    +0.526293 (if age, 60–74)

    +0.939317 (if age, 75+)

    +0 (if gender, female)

    +0.115300 (if gender, male)

    +0 (if marital, married)

    +0.193418 (if marital, divorced)

    −0.034595 (if marital, single)

    +0.126721 (if marital, widowed)

    −0.008761 (if marital, other/unknown)

    +0 (if site, supratentorial)

    +0.112518 (if site, infratentorial)

    +0.134057 (if site, overlapping)

    +0.159675 (if site, brain, NOS)

    +0 (if subtype, DLBCL)

    −0.645093 (if subtype, non-DLBCL)

    −0.085316 (if subtype, lymphoma, NOS)

    +0 (if surgery, biopsy)

    −0.247200 (if surgery, STR)

    −0.667991 (if surgery, GTR)

    −0.163686 (if surgery, partial lobectomy)

    −0.330330 (if surgery, lobectomy)

    −0.152034 (if surgery, unknown-type)

    +0 (if radiation, NO)

    −0.180341 (if radiation, Yes)

    +0 (if chemotherapy, NO)

    −0.908290 (if chemotherapy, Yes)

    +0 (if coexistence, only one)

    −0.682990 (if coexistence, multi-primaries)

    +0 (if HIV, negative)

    +1.214581 (if HIV, positive)

  Estimated 1-year survival probability $=0.814123^{\exp(\text{model})}$

  Estimated 3-year survival probability $=0.6765877^{\exp(\text{model})}$

  Estimated 5-year survival probability $=0.5864965^{\exp(\text{model})}$

Cancer-specific survival

  Model =0

    +0 (if age, 0–59)

    +0.36130 (if age, 60–74)

    +0.61834 (if age, 75+)

    +0 (if site, supratentorial)

    +0.05679 (if site, infratentorial)

    +0.14933 (if site, overlapping)

    +0.10229 (if site, brain, NOS)

    +0 (if subtype, DLBCL)

    −0.52090 (if subtype, non-DLBCL)

    −0.09284 (if subtype, lymphoma, NOS)

    +0 (if surgery, biopsy)

    −0.19801 (if surgery, STR)

    −0.63428 (if surgery, GTR)

    +0.03171 (if surgery, partial lobectomy)

    −0.25750 (if surgery, lobectomy)

    −0.08247 (if surgery, unknown-type)

    +0 (if chemotherapy, no)

    −0.57635 (if chemotherapy, yes)

    +0 (if coexistence, only one)

    −0.95608 (if coexistence, multi-primaries)

    +0 (if HIV, negative)

    +1.18983 (if HIV, positive)

  Estimated 1-year survival probability $=0.8305324^{\exp(\text{model})}$

  Estimated 3-year survival probability $=0.6941114^{\exp(\text{model})}$

  Estimated 5-year survival probability $=0.6140659^{\exp(\text{model})}$

NOS, not otherwise specified; DLBCL, diffuse large B-cell lymphoma; STR, subtotal resection; GTR, gross total resection; HIV, human immunodeficiency virus.

Table S3 Clinical characteristics of the external validation cohort

Characteristic	Subcategory	No.	Percent (%)
Median survival time	27 months		
Total No.		163	100.0
Status	Alive	103	63.2
	Cancer-specific mortality	59	36.2
	Competing mortality	1	0.6
Age, years	0–59	112	68.7
	60–74	49	30.0
	75+	2	1.2
Gender	Female	68	41.7
	Male	95	58.3
Race	White	0	0
	Black	0	0
	Other/unknown	163	100.0
Marital status	Married	153	93.9
	Divorced	4	2.5
	Single	4	2.5
	Widowed	2	1.2
	Other/unknown	0	0
Tumor site	Supratentorial	78	47.9
	Infratentorial	14	8.6
	Overlapping	71	43.6
	Brain, NOS	0	0
Subtype	DLBCL	162	99.4
	Non-DLBCL	1	0.6
	Lymphoma, NOS	0	0
Surgery	Biopsy	130	79.8
	STR	9	5.5
	GTR	24	14.7
	Partial lobectomy	0	0
	Lobectomy	0	0
	Unknown-type	0	0
Radiation	No	107	65.6
	Yes	56	34.4
Chemotherapy	No	46	28.2
	Yes	117	71.8
Coexistence with other malignancy	No	160	98.2
	Yes	3	1.8
HIV	Negative	163	100.0
	Positive	0	0

NOS, not otherwise specified; DLBCL, diffuse large B-cell lymphoma; STR, subtotal resection; GTR, gross total resection; HIV, human immunodeficiency virus.

Figure S1 Flow diagram of the patient selection process. PCNSL, primary central nervous system lymphoma.


Figure S2 Cumulative incidence function (CIF) curves stratified by age (A), gender (B), race (C), marital status (D), tumor site (E), tumor subtype (F), surgery (G), radiotherapy (H), chemotherapy (I), coexisting malignancies (J), and HIV status (K).

Figure S3 Correlation analysis of factors including year, age, gender, race, marital status, tumor site, tumor subtype, radiotherapy, chemotherapy, surgery, coexisting malignancies, HIV status, and survival time.

Figure S4 Forest plots showing hazard ratios (HRs) of the prognostic factors of the overall survival (OS) (A) and cancer-specific survival (CSS) (B) models in the training set.

A Individualized Survival Prediction of Primary Central Nervous System Lymphoma

Overall Survival

Age: 0-59

Gender: ● Female ○ Male

Marital status: Married

Tumor site: Supratentorial

Pathological subtype: DLBCL

Surgery: Biopsy

Radiation: ● NO ○ Yes

Chemotherapy: ● NO ○ Yes

Have other malignancy: ● NO ○ Yes

HIV infection: ● Negative ○ Positive

[Submit]

Estimated Years	Survival probability
<1-year	0.91
1-year	0.814
2-year	0.734
3-year	0.677
4-year	0.624
5-year	0.586
6-year	0.554
7-year	0.531
8-year	0.507
9-year	0.486
10-year	0.471
15-year	0.404
20-year	0.364
25-year	0.325
30-year	0.294
35-year	0.274
40-year	0.248

paper title: Nomograms for Predicting Cancer-Specific Survival for Patients With Primary Central Nervous System Lymphoma: A Population-Based Analysis
For more information, please contact: Chuanwei Yang (yangcw08@126.com)

B Individualized Survival Prediction of Primary Central Nervous System Lymphoma

Cancer-Specific Survival

Age: 0-59

Tumor site: Supratentorial

Pathological subtype: DLBCL

Surgery: Biopsy

Chemotherapy: ● NO ○ Yes

Have other malignancy: ● NO ○ Yes

HIV infection: ● Negative ○ Positive

[Submit]

Estimated Years	Survival probability
<1-year	0.919
1-year	0.831
2-year	0.749
3-year	0.694
4-year	0.645
5-year	0.614
6-year	0.578
7-year	0.552
8-year	0.53
9-year	0.509
10-year	0.489
15-year	0.418
20-year	0.373
25-year	0.339
30-year	0.296
35-year	0.264
40-year	0.239

paper title: Nomograms for Predicting Cancer-Specific Survival for Patients With Primary Central Nervous System Lymphoma: A Population-Based Analysis
For more information, please contact: Chuanwei Yang (yangcw08@126.com)

Figure S5 Free software for individualized prediction of overall survival (OS) (A) and cancer-specific survival (CSS) (B) in patients with PCNSL. OS, overall survival; CSS, cancer-specific survival; PCNSL, primary central nervous system lymphoma.

Figure S6 Subgroup analysis of the overall survival (OS) and cancer-specific survival (CSS) in the primary central nervous system lymphoma (PCNSL) patient cohort with or without HIV infection or coexisting malignancies. Forest plots showing hazard ratio (HR) of the prognostic factors of the CSS models in the subgroup of patients with PCNSL only (A), in the subgroup of patients with multiple malignancies (B), in the subgroup of patients who were HIV negative (C), and in the subgroup of patients who were HIV positive (D).